Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Advances in the Interaction of Nanomaterials and Biosystems (Enzymes, Proteins,...
share announcement

Advances in the Interaction of Nanomaterials and Biosystems (Enzymes, Proteins, Peptides)

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 June 2024) | Viewed by 4960

Special Issue Editors

Dr. Maciej Serda

E-Mail Website
Guest Editor
Institute of Chemistry, University of Silesia in Katowice, 40-006 Katowice, Poland
Interests: nanomedicine; fullerene nanomaterials; photodynamic therapy; kinase inhibitors
Dr. Tainah Dorina Marforio

E-Mail Website
Guest Editor
Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum—Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy
Interests: boron neutron capture therapy; protein-ligand interactions; drug delivery; proteins-ligand interaction

Special Issue Information

Dear Colleagues,

Due to their peculiar properties, nanomaterials are nowadays widely employed in biomedical applications. In this field, the mode of action of nanomaterials relies on their interaction with proteins, enzymes, peptides, nucleic acids and lipids, which are ubiquitous in physiological environments. In order to tune, engineer, develop and create novel platforms, it is crucial to understand and decipher how the dyad “nanomaterial–biosystem” interacts. This knowledge is fundamental to develop novel nano-medical, -diagnostic and -therapeutic systems. We invite researchers working on nanomaterials in the biomedical field, with a particular interest in deciphering the interaction between biosystems and nanomaterials, to contribute to this issue.

Dr. Maciej Serda
Dr. Tainah Dorina Marforio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials
  • proteins
  • biosystems
  • interactions
  • drug delivery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

30 pages, 19762 KiB  
Article
Stabilization of Graphene Oxide Dispersion in Plasma-like Isotonic Solution Containing Aggregating Concentrations of Bivalent Cations
by Marcin Z. Krasoń, Anna Paradowska, Martyna Fronczek, Mateusz Lejawa, Natalia Kamieńska, Michał Krejca, Anna Kolanowska, Sławomir Boncel and Marek W. Radomski
Pharmaceutics 2023, 15(10), 2495; https://doi.org/10.3390/pharmaceutics15102495 - 19 Oct 2023
Cited by 1 | Viewed by 1674
Abstract
Graphene oxide’s (GO) intravascular applications and biocompatibility are not fully explored yet, although it has been proposed as an anticancer drug transporter, antibacterial factor or component of wearable devices. Bivalent cations and the number of particles’ atom layers, as well as their structural [...] Read more.
Graphene oxide’s (GO) intravascular applications and biocompatibility are not fully explored yet, although it has been proposed as an anticancer drug transporter, antibacterial factor or component of wearable devices. Bivalent cations and the number of particles’ atom layers, as well as their structural oxygen content and pH of the dispersion, all affect the GO size, shape, dispersibility and biological effects. Bovine serum albumin (BSA), an important blood plasma protein, is expected to improve GO dispersion stability in physiological concentrations of the precipitating calcium and magnesium cations to enable effective and safe tissue perfusion. Methods: Four types of GO commercially available aqueous dispersions (with different particle structures) were diluted, sonicated and studied in the presence of BSA and physiological cation concentrations. Nanoparticle populations sizes, electrical conductivity, zeta potential (Zetasizer NanoZS), structure (TEM and CryoTEM), functional groups content (micro titration) and dispersion pH were analyzed in consecutive preparation stages. Results: BSA effectively prevented the aggregation of GO in precipitating concentrations of physiological bivalent cations. The final polydispersity indexes were reduced from 0.66–0.91 to 0.36–0.43. The GO-containing isotonic dispersions were stable with the following Z-ave results: GO1 421.1 nm, GO2 382.6 nm, GO3 440.2 nm and GO4 490.1 nm. The GO behavior was structure-dependent. Conclusion: BSA effectively stabilized four types of GO dispersions in an isotonic dispersion containing aggregating bivalent physiological cations. Full article
(This article belongs to the Special Issue Advances in the Interaction of Nanomaterials and Biosystems (Enzymes, Proteins, Peptides))
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

29 pages, 6185 KiB  
Review
Mesoporous Silica Nanoparticles: Types, Synthesis, Role in the Treatment of Alzheimer’s Disease, and Other Applications
by Bhagavathi Sundaram Sivamaruthi, Devesh U. Kapoor, Rajiv R. Kukkar, Mansi Gaur, Gehan M. Elossaily, Bhupendra G. Prajapati and Chaiyavat Chaiyasut
Pharmaceutics 2023, 15(12), 2666; https://doi.org/10.3390/pharmaceutics15122666 - 24 Nov 2023
Cited by 2 | Viewed by 2792
Abstract
Globally, many individuals struggle with Alzheimer’s disease (AD), an unrelenting and incapacitating neurodegenerative condition. Despite notable research endeavors, effective remedies for AD remain constrained, prompting the exploration of innovative therapeutic avenues. Within this context, silica-based nanoplatforms have emerged with pronounced potential due to [...] Read more.
Globally, many individuals struggle with Alzheimer’s disease (AD), an unrelenting and incapacitating neurodegenerative condition. Despite notable research endeavors, effective remedies for AD remain constrained, prompting the exploration of innovative therapeutic avenues. Within this context, silica-based nanoplatforms have emerged with pronounced potential due to their unique attributes like expansive surface area, customizable pore dimensions, and compatibility with living systems. These nanoplatforms hold promise as prospective interventions for AD. This assessment provides a comprehensive overview encompassing various forms of mesoporous silica nanoparticles (MSNs), techniques for formulation, and their applications in biomedicine. A significant feature lies in their ability to precisely guide and control the transport of therapeutic agents to the brain, facilitated by the adaptability of these nanoplatforms as drug carriers. Their utility as tools for early detection and monitoring of AD is investigated. Challenges and prospects associated with harnessing MSNs are studied, underscoring the imperative of stringent safety evaluations and optimization of how they interact with the body. Additionally, the incorporation of multifunctional attributes like imaging and targeting components is emphasized to enhance their efficacy within the intricate milieu of AD. As the battle against the profound repercussions of AD persists, MSNs emerge as a promising avenue with the potential to propel the development of viable therapeutic interventions. Full article
(This article belongs to the Special Issue Advances in the Interaction of Nanomaterials and Biosystems (Enzymes, Proteins, Peptides))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop